Danish pharmaceutical giant has been steadily expanding its presence in India, and the arrival of Ozempic marks a significant move in a country grappling with fast-rising rates of type 2 diabetes and ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a critical battleground for drugmakers ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing ...

The blockbuster drug, marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, has been at the ...

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...

Eli Lilly has seen revenue soar thanks to its blockbuster weight loss drug portfolio. Lilly and Novo Nordisk dominate this ...

" We are doing $1-2 million run rate revenue in the US. We expect the US business to be larger than India. We are in ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the ...